Hosted on MSN

Biogen’s (NASDAQ: BIIB) Q4 CY2025: Strong sales

Biotech company Biogen (NASDAQ:BIIB) reported Q4 CY2025 results , but sales fell by 7.1% year on year to $2.28 billion. Its non-GAAP profit of $1.99 per share was 22.1% above analysts’ consensus ...
Seeking Alpha

Biogen: Investors Are Missing The Bigger Picture

Biogen is an intriguing stock that occupies one of the leading positions in the central nervous system therapeutic market. On May 1, it released fairly strong financial results for the first quarter ...
Business Insider

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI ® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE ® ...
FiercePharma

Biogen, eyeing swift commercial tailwind, ponies up $5.6B for Apellis and its 2 approved meds

Despite a healthy roster of late-stage assets and a revenue turnaround in 2025, it’s no secret that Biogen has been seeking near-term sales drivers ahead of its planned product rollouts later in the ...